Sichuan Biokin Pharmaceutical Co., Ltd. Class A
SSSE:688506253.00
CNY
+0.90
(+0.36%)
ISIN
CNE100006FN4
Return %
Stock
S&P 500
1Y
-28.73
14.20
3Y
176.84
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yi Zhu
- Full Time Employees
- 3,198
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Chengdu China
- IPO Date
- Jan 6, 2023
- Website
- baili-pharm.com
- Similar Companies
- Business
- Sichuan Biokin Pharmaceutical Co., Ltd. is a vertically integrated, commercial-stage biopharmaceutical enterprise focused on the research, development, manufacturing, and global commercialization of innovative biologics, antibody-drug conjugates, chemical pharmaceuticals, and modern traditional medicine formulations. Founded in 1996 and headquartered in Chengdu, Sichuan Province, China, the company operates integrated research and development centers and production facilities across China and the United States, conducting international drug development primarily through its United States research and development subsidiary, SystImmune, Inc., based in Redmond, Washington. Sichuan Biokin Pharmaceutical operates across innovative oncology biopharmaceuticals and commercialized pharmaceutical formulations, offering a broad spectrum of products and services that include proprietary antibody-drug conjugates (ADCs) such as BL-B01D1, a first-in-class bispecific EGFR x HER3 antibody-drug conjugate; BL-M07D1, a Trop-2-targeted antibody-drug conjugate; BL-M02D1, a HER2-targeted antibody-drug conjugate; bispecific and multi-specific antibody therapeutics developed via proprietary platforms including SEBA (Specific Efficient Bispecific Antibody) and GNC (Guidance and Navigating Cell engager tetra-specific platform), comprising SI-B001, GNC-038, and GNC-035 for solid tumors and hematologic malignancies; commercialized chemical generics, injectables, oral liquid formulations, and modern Chinese patent medicines targeting anti-infective, pediatric, cardiovascular, neurological, respiratory, and gastrointestinal therapeutic areas; active pharmaceutical ingredients; and contract development and clinical research services. In recent strategic corporate developments, the company executed a landmark global exclusive collaboration and license agreement with Bristol Myers Squibb through SystImmune for the global co-development and commercialization of BL-B01D1, securing an upfront payment of 800 million dollars and potential milestone payments totaling up to 8.4 billion dollars. Following its initial public offering on the Shanghai Stock Exchange STAR Market (SSE: 688506), Sichuan Biokin Pharmaceutical has accelerated multi-regional clinical trials across North America, Europe, and Asia, advanced multiple Phase II and Phase III registrational studies for its bispecific ADC pipeline in non-small cell lung cancer, breast cancer, and other solid tumors, and expanded its commercial-scale biomanufacturing and research infrastructure.